Condition
B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative clinical trials and research
As of November 12, 2026, Find a Trial lists 4 B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative clinical trials that are recruiting, at sites in 3 countries (most in United States (3), China (1), Puerto Rico (1)). By phase: Phase 2 (3), Phase 1/2 (1). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 4Clinical trials
- 3Countries
Newest B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative clinical trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| Full-course immunotherapy plus chemotherapy for newly diagnosed Ph-negative B-cell ALL | Phase 2 | Suzhou, Jiangsu | Recruiting | May 4, 2026 |
| Erwinia asparaginase with chemotherapy for high‑risk adults with newly diagnosed Philadelphia‑negative acute lymphoblastic leukemia or lymphoblastic lymphoma | Phase 2 | Phoenix, Arizona and 7 other locations | Recruiting | Apr 9, 2025 |
| Inotuzumab ozogamicin and blinatumomab with optional ponatinib for CD22-positive B-cell acute lymphoblastic leukemia | Phase 2 | Birmingham, Alabama and 284 other locations | Recruiting | Nov 14, 2018 |
| Using inotuzumab ozogamicin with chemotherapy to treat acute lymphoblastic leukemia | Phase 1/2 | Houston, Texas | Recruiting | Jun 13, 2011 |
All recruiting trials (4)
-
Full-course immunotherapy plus chemotherapy for newly diagnosed Ph-negative B-cell ALL
This phase 2 test gives blinatumomab throughout treatment with reduced-dose chemotherapy, and uses CAR-T cells and transplant as needed, to try to improve two-year relapse-free survival in adults with newly diagnosed Ph-negative B-cell ALL.
-
Erwinia asparaginase with chemotherapy for high‑risk adults with newly diagnosed Philadelphia‑negative acute lymphoblastic leukemia or lymphoblastic lymphoma
This trial tries Erwinia-derived asparaginase together with induction and consolidation chemotherapy in adults 18–54 with newly diagnosed high‑risk, Philadelphia chromosome–negative ALL or lymphoblastic lymphoma.
-
Inotuzumab ozogamicin and blinatumomab with optional ponatinib for CD22-positive B-cell acute lymphoblastic leukemia
This trial will test whether inotuzumab ozogamicin followed by blinatumomab, with or without ponatinib, can help people with CD22-positive B-cell acute lymphoblastic leukemia who are newly diagnosed, have relapsed, or are refractory to prior therapy.
-
Using inotuzumab ozogamicin with chemotherapy to treat acute lymphoblastic leukemia
This study is testing if a new drug combined with lighter chemotherapy can help older patients with acute lymphoblastic leukemia who can't handle stronger treatments.
Related topics
Quick answers
How many B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative clinical trials are recruiting right now?
4, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 3 countries. The most sites are in United States (3 trials), China (1 trial), Puerto Rico (1 trial). Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 2: 3, Phase 1/2: 1. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.